Restless Legs Syndrome: Is Treatable But Under-Recognised
BMJ 333:457-458, Medcalf,P. &Bhatia,K.P., 2006
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
Postpartum Cerebral Angiopathy Possibly Due to Bromocriptine Therapy
Stroke 26:128-130, Janssens,E.,et al, 1995
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Treatment of Advanced Parkinson Disease With Pergolide
Neurol 31:675-682, Lieberman,A.,et al, 1981
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Falling Asleep at the Wheel:Motor Vehicle Mishaps in Persons Taking Pramipexole and Ropinirole
Neurol 52:1908-1910, Frucht,S.,et al, 1999
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Acromegaly
NEJM 322:966-977, Melmed,S., 1990